Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 131
   

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2 2015’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 18
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 21
A1M Pharma AB 21
Adrenomed AG 22
Am-Pharma B.V. 23
Angion Biomedica Corp. 24
Bolder Biotechnology, Inc. 25
Cellmid Limited 26
Complexa, Inc. 27
DiaMedica Inc. 28
Digna Biotech, S.L. 29
DURECT Corporation 30
F. Hoffmann-La Roche Ltd. 31
G1 Therapeutics, Inc. 32
Hadasit Medical Research Services & Development Ltd 33
Kringle Pharma, Inc. 34
NephroGenex, Inc. 35
NeuroVive Pharmaceutical AB 36
Noorik Biopharmaceuticals AG 37
Nyken BV 38
Opsona Therapeutics Limited 39
Orion Oyj 40
ProMetic Life Sciences Inc. 41
Quark Pharmaceuticals, Inc. 42
STATegics, Inc. 43
Thrasos, Inc. 44
Torrent Pharmaceuticals Limited 45
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
A1M-001 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
adrecizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BB-3 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BBT-030 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BBT-045 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CAB-101 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Cardiotrophin-1 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CXA-10 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
cyclosporine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DM-199 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DUR-928 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HYPER-IL-6 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
KP-100IT - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
levosimendan - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MTP-131 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
N-003 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
NYK-1341 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
OPN-305 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PBI-4419 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pyridoxamine dihydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
QPI-1002 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
R-190 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Recombinant Human Alkaline Phosphatase - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
RLS-003 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
RO-6839328 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
STSE-15 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
THR-184 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
TRC-160334 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates 101
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 121
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 122
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 123
Featured News & Press Releases 123
Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury 123
Jun 09, 2015: Angion Biomedica To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury 123
Mar 27, 2015: NephroGenex Announces Data on Acute Kidney Injury at National Kidney Foundation 2015 Spring Clinical Meetings 124
Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 125
Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 125
Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases 126
Jan 20, 2015: AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury 127
Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury 127
Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury 128
Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury 128
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015 11
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2015 21
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2015 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2015 23
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2015 24
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bolder Biotechnology, Inc., H2 2015 25
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2015 26
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2015 27
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2015 28
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2015 29
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2015 30
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 31
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2015 32
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015 33
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2015 34
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2015 35
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2015 36
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2015 37
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H2 2015 38
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Opsona Therapeutics Limited, H2 2015 39
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2015 40
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2015 41
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 42
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2015 43
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos, Inc., H2 2015 44
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2015 45
Assessment by Monotherapy Products, H2 2015 46
Number of Products by Stage and Target, H2 2015 48
Number of Products by Stage and Mechanism of Action, H2 2015 50
Number of Products by Stage and Route of Administration, H2 2015 52
Number of Products by Stage and Molecule Type, H2 2015 54
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H2 2015 101
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2015 121
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2015 122

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015 11
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 46
Number of Products by Top 10 Targets, H2 2015 47
Number of Products by Stage and Top 10 Targets, H2 2015 47
Number of Products by Top 10 Mechanism of Actions, H2 2015 49
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 49
Number of Products by Routes of Administration, H2 2015 51
Number of Products by Stage and Routes of Administration, H2 2015 51
Number of Products by Molecule Types, H2 2015 53
Number of Products by Stage and Molecule Types, H2 2015 53

Published By: Global Markets Direct
Product Code: Global Markets Direct13304


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: